AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Cryo-Cell Reports Q2 2025 Financial Results: Revenue Down 1% YoY
ByAinvest
Wednesday, Jul 16, 2025 1:14 pm ET1min read
Cryo-Cell International reported a 1% decrease in revenue to $7.9 million in Q2 2025, compared to $8.0 million in Q2 2024. Net income fell to $356,000 from $656,000. The company continues to focus on premier cord blood and tissue cryopreservation services and cellular therapies.
Cryo-Cell International, Inc. (NYSE American LLC: CCEL), a leading provider of cord blood and tissue cryopreservation services, reported its fiscal second quarter 2025 financial results on July 15, 2025. The company announced a 1% decrease in revenue to $7.9 million compared to $8.0 million in the same period last year. Net income fell to $356,000 from $656,000.The revenue decline was primarily driven by a decrease in processing and storage fee revenue, which accounted for $7.87 million in Q2 2025 compared to $7.97 million in Q2 2024. Public banking revenue and product revenue also decreased, contributing to the overall revenue drop.
Despite the revenue decline, Cryo-Cell continues to focus on its core business of providing premier cord blood and tissue cryopreservation services and developing cellular therapies. The company's public banking program, in partnership with Duke University, has provided cord blood for more than 700 transplants and operates donation sites in prominent hospitals such as Cedars-Sinai Hospital in Los Angeles.
Cryo-Cell's mission remains to improve the lives of patients worldwide by offering high-quality and cost-effective biostorage solutions. The company's exclusive rights to PrepaCyte-CB, the industry's most advanced cord blood processing technology, further solidifies its position in the market.
Forward-looking statements indicate that Cryo-Cell is committed to expanding its global presence and diversifying its product offerings, including the addition of ExtraVault services. However, the company acknowledges several risks and uncertainties, including the success of its expansion initiatives, product diversification, and future competitive positions.
References:
[1] https://www.marketscreener.com/quote/stock/CRYO-CELL-INTERNATIONAL-I-120786854/news/Cryo-Cell-International-Earnings-Release-Q2-2025-50517657/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet